- Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
-
Yi Z, Ma F
- KMID: 2398200
- J Breast Cancer.
- 2017 Dec;20(4):321-326.
- doi: 10.4048/jbc.2017.20.4.321
Activation of the mammalian target of rapamycin (mTOR) signaling pathway is an important mechanism of resistance to endocrine therapy in breast cancer. Everolimus, an mTOR inhibitor, has been shown to... -
- CITED
-
- Close
- SHARE
-
- Close
- Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma
-
Jeon SY, Yhim HY, Lee NR, Song EK, Kwak JY, Yim CY
- KMID: 2371662
- Korean J Intern Med.
- 2017 Mar;32(2):365-368.
- doi: 10.3904/kjim.2015.121
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Experience of a Single Center in Treating Multiple Manifestations of Tuberous Sclerosis Complex with Everolimus
-
Ahn H, Yum MS, Jang HN, Song C, Ko TS
- KMID: 2470590
- Ann Child Neurol.
- 2019 Dec;27(4):135-145.
- doi: 10.26815/acn.2019.00206
PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, for the treatment of tuberous sclerosis complex... -
- CITED
-
- Close
- SHARE
-
- Close
- Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report
-
Lee SR, Kim YM, Jung JY, Kim HJ, Kim DH, Park KW, Lee SI
- KMID: 2264575
- Korean J Med.
- 2012 Oct;83(4):520-524.
Everolimus, an inhibitor of the mammalian target of rapamycin, is an active agent against metastatic renal cell carcinoma. Treatment with everolimus prolongs progression-free survival in patients with clear cell-type renal... -
- CITED
-
- Close
- SHARE
-
- Close
- Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
-
Park SM, Kim BS, Kim MB, Lee YJ, Ko HC
- KMID: 2414696
- Ann Dermatol.
- 2018 Apr;30(2):247-249.
- doi: 10.5021/ad.2018.30.2.247
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Case Report of Everolimus-Associated DKA in a Patient with Metastatic Renal Cell Carcinoma
-
Kim LK, Ahn CH, Lee JE, Jung CH, Koo BK, Moon MK
- KMID: 2269343
- Korean J Med.
- 2014 Jun;86(6):761-765.
Everolimus, an inhibitor of the mammalian target of the rapamycin (mTOR) pathway, is widely used as an immunosuppressant for the prevention of organ rejection following transplant and to treat metastatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Oral Everolimus Reduces Adventitial Cell Activation and Neointima Formation in Balloon-Injured Rat Carotid Artery
-
Moon KW, Lee JM, Chang K, Yoo KD, Jeon DS, Youn HJ, Chung WS, Lee MY, Kim JJ, Seung KB, Kim CM, Hong SJ
- KMID: 2227194
- Korean Circ J.
- 2004 Oct;34(10):983-991.
- doi: 10.4070/kcj.2004.34.10.983
BACKGROUND AND OBJECTIVES: Previous studies suggest that phenotypic conversion, proliferation and migration of adventitial fibroblasts after balloon injury have an important role in neointimal formation and vascular remodeling. The present... -
- CITED
-
- Close
- SHARE
-
- Close
- Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma
-
Xu W, Kim JW, Jung WJ, Koh Y, Yoon SS
- KMID: 2411148
- Cancer Res Treat.
- 2018 Apr;50(2):599-613.
- doi: 10.4143/crt.2016.357
PURPOSE: Anaplastic large cell lymphoma (ALCL) is a rare aggresive non-Hodgkin lymphoma, of which over 50% of cases have an aberrant nucleophosmin (NPM)‒anaplastic lymphoma kinase (ALK) fusion protein. Both mechanistic... -
- CITED
-
- Close
- SHARE
-
- Close
- Cross-sectional analysis of immunosuppressive regimens focused on everolimus after liver transplantation in a Korean high-volume transplantation center
-
Kang SH, Hwang S, Ha TY, Song GW, Jung DH, Ahn CS, Moon DB, Kim KH, Park GC, Yoon YI, Park YH, Cho HD, Kwon JH, Chung YK, Choi JU, Lee SG
- KMID: 2468159
- Korean J Transplant.
- 2019 Dec;33(4):98-105.
- doi: 10.4285/jkstn.2019.33.4.98
BACKGROUND: The mammalian target of the rapamycin inhibitor has dual inhibitory effects on cell growth and angiogenesis. This study aimed to analyze the usage of everolimus on actual immunosuppression (IS)... -
- CITED
-
- Close
- SHARE
-
- Close
- Optimal Treatment of Advanced Pancreatic Neuroendocrine Tumor
-
Kim YS, Cho JH
- KMID: 2448526
- Korean J Pancreas Biliary Tract.
- 2016 Jul;21(3):128-137.
- doi: 10.15279/kpba.2016.21.3.128
Pancreatic neuroendocrine tumors (pNETs) are diverse diseases with different prognosis. Among available various therapeutic options, curative resection should be considered for localized tumors and in some selected cases of metastatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Heart Retransplantation to Treat a Case of Refractory Cardiac Allograft Vasculopathy
-
Lee SY, Choi JO, Kim YJ, Choi JS, Lee GY, Kim JS, Jeon ES
- KMID: 2361435
- Korean J Med.
- 2016 Dec;91(3):287-291.
- doi: 10.3904/kjm.2016.91.3.287
Cardiac allograft vasculopathy is one of the most important causes of poor long-term survival after heart transplantation. The condition tends to be diffuse, usually affecting the mid-to-distal portions of the... -
- CITED
-
- Close
- SHARE
-
- Close
- Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy
-
Lee SC, Kim KH, Kim OH, Lee SK, Hong HE, Choi BJ, Jeong W, Kim SJ
- KMID: 2417890
- Cancer Res Treat.
- 2018 Jul;50(3):1023-1038.
- doi: 10.4143/crt.2017.085
PURPOSE: Everolimus only inhibits mammalian target of rapamycin complex 1 (mTORC1), whereas Ku0063794 inhibits both mTORC1 and mTORC2. Although they have similar anticancer effects, their combination has a synergistic effect... -
- CITED
-
- Close
- SHARE
-
- Close
- Kounis Syndrome Presenting as Very Late Stent Thrombosis in an Everolimus-Eluting Stent Following Wasp Stings
-
Min JH, Kang MH
- KMID: 2224847
- Korean Circ J.
- 2013 Aug;43(8):561-564.
- doi: 10.4070/kcj.2013.43.8.561
Kounis syndrome is the concurrence of acute coronary syndromes with conditions associated with mast cell activation following an allergic insult. We report a 56-year-old man who experienced a ST-segment elevation... -
- CITED
-
- Close
- SHARE
-
- Close
- A cross-sectional analysis of long-term immunosuppressive regimens after liver transplantation at Asan Medical Center: Increased preference for mycophenolate mofetil
-
Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Lee SG
- KMID: 2409076
- Ann Hepatobiliary Pancreat Surg.
- 2018 Feb;22(1):19-26.
- doi: 10.14701/ahbps.2018.22.1.19
BACKGROUNDS/AIMS: Long-term immunosuppression regimens after liver transplantation (LT) are rarely reported in detail. We aimed to provide information on actual long-term immunosuppression regimens through this cross-sectional study. METHODS: Our institutional LT... -
- CITED
-
- Close
- SHARE
-
- Close
- Proliferation Signal Inhibitors: Sirolimus and Everolimus
-
Kim JK
- KMID: 2201822
- J Korean Soc Transplant.
- 2006 Dec;20(2):143-148.
Proliferation signal inhibitors are a new class of immunosuppressant. They inhibit the mammalian target of rapamycin and blocks the cell cycle of various cell types, including T and B lymphocytes.... -
- CITED
-
- Close
- SHARE
-
- Close
- The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers
-
Hwang GY, Choi SY, Chang IH
- KMID: 2457590
- Korean J Urol Oncol.
- 2019 Aug;17(2):75-80.
- doi: 10.22465/kjuo.2019.17.2.75
To systematically review relevant literature on efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with advanced and metastatic urothelial cell cancer (UCC), renal cell cancer (RCC), and prostate... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
-
Park K, Lee JL, Ahn JH, Lee KH, Jeong IG, Song C, Hong B, Hong JH, Ahn H
- KMID: 2380371
- Cancer Res Treat.
- 2014 Oct;46(4):339-347.
- doi: 10.4143/crt.2013.154
PURPOSE: The purpose of this study is to assess the efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC) for whom initial treatment with a... -
- CITED
-
- Close
- SHARE
-
- Close
- Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside
-
Kim HJ, Edelstein
- KMID: 2224211
- Kidney Res Clin Pract.
- 2012 Sep;31(3):132-138.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common life-threatening hereditary disease in the USA resulting in chronic kidney disease and the need for dialysis and transplantation. Approximately 85%... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and Efficacy of the Early Introduction of Everolimus (Certican(R)) with Low Dose of Cyclosporine in de Novo Kidney Recipients after 1 Month of Transplantation (Preliminary Results)
-
Oh CK, Ha JW, Kim YH, Kim YL, Kim YS
- KMID: 2324214
- J Korean Soc Transplant.
- 2012 Jun;26(2):83-91.
BACKGROUND: Everolimus and cyclosporine (CsA) exhibit synergistic immunosuppressive activity when used in combination. We analyzed preliminary data about the use of everolimus with a CsA-sparing strategy in de novo renal... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy and Targeted Therapy beyond Adenocarcinoma of the Lung: Neuroendocrine Carcinoma
-
Kwon JH
- KMID: 2268883
- Korean J Med.
- 2016 Jan;90(1):7-14.
- doi: 10.3904/kjm.2016.90.1.7
Neuroendocrine carcinoma (NEC) has been reported to comprise 25% of lung cancer cases. NEC is classified as typical carcinoid, atypical carcinoid, large-cell neuroendocrine carcinoma, and small-cell lung cancer. Carcinoid tumors... -
- CITED
-
- Close
- SHARE
-
- Close
